A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Enrolling by invitation

Conditions studied: Cancer

In brief

The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.

Key facts

Study ID

NCT06701201

Run by

Verismo Therapeutics

People needed

60

Starts

2025-01-27

Expected to finish

2042-02-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants are eligible to be included in the study only if all of the following criteria apply:
• All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics.
• Participant is willing and able to comply with the study requirements.

You may not qualify if…

• There are no specific exclusion criteria.

Where it is running

• Colorado Blood Cancer Institute, part of Sarah Cannon Research Institute — Denver, Colorado, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• University of Kansas Cancer Center — Westwood, Kansas, United States
• Rutgers Cancer Institute — New Brunswick, New Jersey, United States
• University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.